Michael Hayden, MB, ChB, PhD, FRCP, FRSC, The University of British Columbia, Vancouver, Canada, shares the findings of an analysis of the Phase III PROOF-HD trial, (NCT04556656) assessing the efficacy and safety of pridopidine in patients with early-stage Huntington’s disease (HD) without antidopaminergic medications (ADMs). The randomized, double-blind, placebo-controlled trial assessed mean change in Total Functional Capacity (TFC) and composite Unified Huntington Disease Rating Scale (cUHDRS) scores as its primary and secondary endpoints, respectively, failing to show a difference in rate of decline compared to placebo. However, in a pre-specified analysis excluding patients on neuroleptics or anti-chorea medications, all outcome measures were significantly improved or stabilized for at least one year and were better than placebo up to week 78. This evidence has been replicated in a new independent integrated efficacy analysis of four previous studies, where individuals treated with pridopidine without ADMs showed significant benefits on change in TFC and cUHDRS scores. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
